TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

AURYXIA

FERRIC CITRATE
Hematology Approved 2014-09-05
2
Indications
--
Phase 3 Trials
11
Years on Market

Details

Status
Prescription
First Approved
2014-09-05
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: FERRIC CITRATE

AURYXIA Approval History

Loading approval history...

What AURYXIA Treats

3 indications

AURYXIA is approved for 3 conditions since its original approval in 2014. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hyperphosphatemia
  • Chronic Kidney Disease
  • Iron Deficiency Anemia
Source: FDA Label

Drugs Similar to AURYXIA

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

FERAHEME
FERUMOXYTOL
2 shared
COVIS
Shared indications:
Iron Deficiency AnemiaChronic Kidney Disease
FERRLECIT
SODIUM FERRIC GLUCONATE COMPLEX
2 shared
Sanofi
Shared indications:
Iron Deficiency AnemiaChronic Kidney Disease
FERUMOXYTOL
FERUMOXYTOL
2 shared
Novartis
Shared indications:
Iron Deficiency AnemiaChronic Kidney Disease
INJECTAFER
FERRIC CARBOXYMALTOSE
2 shared
AM REGENT
Shared indications:
Iron Deficiency AnemiaChronic Kidney Disease
IRON SUCROSE
IRON SUCROSE
2 shared
Novartis
Shared indications:
Iron Deficiency AnemiaChronic Kidney Disease
MONOFERRIC
FERRIC DERISOMALTOSE
2 shared
PHARMACOSMOS
Shared indications:
Iron Deficiency AnemiaChronic Kidney Disease
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE
SODIUM FERRIC GLUCONATE COMPLEX
2 shared
Hikma
Shared indications:
Iron Deficiency AnemiaChronic Kidney Disease
DOXERCALCIFEROL
DOXERCALCIFEROL
1 shared
CAPLIN
Shared indications:
Chronic Kidney Disease
EPOGEN/PROCRIT
EPOETIN ALFA
1 shared
Amgen
Shared indications:
Chronic Kidney Disease
FARXIGA
DAPAGLIFLOZIN
1 shared
AstraZeneca
Shared indications:
Chronic Kidney Disease
FUROSCIX
FUROSEMIDE
1 shared
SCPHARMACEUTICALS
Shared indications:
Chronic Kidney Disease
INPEFA
SOTAGLIFLOZIN
1 shared
LEXICON PHARMS INC
Shared indications:
Chronic Kidney Disease
JARDIANCE
EMPAGLIFLOZIN
1 shared
Boehringer Ingelheim
Shared indications:
Chronic Kidney Disease
KERENDIA
FINERENONE
1 shared
Bayer
Shared indications:
Chronic Kidney Disease
KORSUVA
DIFELIKEFALIN ACETATE
1 shared
VIFOR INTL
Shared indications:
Chronic Kidney Disease
MIRCERA
METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA
1 shared
HOFFMAN-LA ROCHE
Shared indications:
Chronic Kidney Disease
PARSABIV
ETELCALCETIDE
1 shared
KAI PHARMS INC
Shared indications:
Chronic Kidney Disease
RAYALDEE
CALCIFEDIOL
1 shared
EIRGEN
Shared indications:
Chronic Kidney Disease
RENVELA
SEVELAMER CARBONATE
1 shared
Sanofi
Shared indications:
Chronic Kidney Disease
RETACRIT
EPOETIN ALFA-EPBX
1 shared
Pfizer
Shared indications:
Chronic Kidney Disease
πŸ”¬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
πŸ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

AURYXIA FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Auryxia is a phosphate binder indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis. Auryxia is an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis. 1.1 Hyperphosphatemia in Chronic Kidney Disease on Dialysis Auryxia is indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis. 1.2 Iron Deficiency Anemia in Chronic Kidney Disease Not on Dialysis Auryxia is indicated for the treatment of iron def...

AURYXIA Patents & Exclusivity

Latest Patent: Jul 2030

Patents (3 active)

US10300039 Expires Jul 21, 2030
US9387191 Expires Jul 21, 2030
US8093423 Expires Apr 21, 2026
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.